CliffBio
small molecule

AUVI-Q

EPINEPHRINE

Loss of exclusivityNovember 2029latest FDA-listed patent expiry
CompanyKaleo →View the full company profile on CliffBio

Drug detail

Brand nameAUVI-Q
Active ingredientEPINEPHRINE
StrengthEQ 0.3MG/DELIVERY
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalAugust 2012
Marketing statusRX

Listed patents

PatentExpiresType
8021344November 2029product
8226610April 2029product
8231573November 2028product
7947017March 2028product
8206360February 2027product
11590286December 2026product

More from Kaleo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AUVI-Q patent cliff — loss of exclusivity November 2029 | CliffBio